{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:36:47Z","timestamp":1790195807908,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.pt.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T16:36:57Z","timestamp":1588783017000},"page":"573-575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?"],"prefix":"10.1016","volume":"36","author":[{"given":"Josu\u00e9","family":"de Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Geary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2020.04.005_bb0005","series-title":"Transforming Our World: The 2030 Agenda for Sustainable Development","author":"United Nations","year":"2015"},{"key":"10.1016\/j.pt.2020.04.005_bb0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/d41573-020-00001-7","article-title":"2019 FDA drug approvals","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pt.2020.04.005_bb0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/d41573-019-00014-x","article-title":"2018 FDA drug approvals","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pt.2020.04.005_bb0020","first-page":"633","article-title":"Progress report on the elimination of human onchocerciasis, 2017-2018","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly. Epidem. Rec."},{"key":"10.1016\/j.pt.2020.04.005_bb0025","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(07)60942-8","article-title":"Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study","volume":"369","author":"Osei-Atweneboana","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2020.04.005_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000998","article-title":"Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus","volume":"5","author":"Osei-Atweneboana","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2020.04.005_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002953","article-title":"A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection","volume":"8","author":"Awadzi","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2020.04.005_bb0040","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"Opoku","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2020.04.005_bb0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13071-015-0779-4","article-title":"The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data","volume":"8","author":"Turner","year":"2015","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2020.04.005_bb0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpddr.2019.06.002","article-title":"Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance","volume":"10","author":"Prichard","year":"2019","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2020.04.005_bb0055","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1440-1681.2004.04093.x","article-title":"Randomized trial of a single, double and triple dose of 10 mg\/kg of a human formulation of triclabendazole in patients with fascioliasis","volume":"31","author":"Talaie","year":"2004","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.pt.2020.04.005_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001720","article-title":"Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano","volume":"6","author":"Villegas","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2020.04.005_bb0065","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/trstmh\/trz093","article-title":"Triclabendazole in the treatment of human fascioliasis: a review","volume":"113","author":"Gandhi","year":"2019","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2020.04.005_bb0070","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3201\/eid1806.120302","article-title":"Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands","volume":"18","author":"Winkelhagen","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.pt.2020.04.005_bb0075","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.pt.2016.03.002","article-title":"Current threat of triclabendazole resistance in Fasciola hepatica","volume":"32","author":"Kelley","year":"2016","journal-title":"Trends Parasitol."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492220301021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492220301021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:34:30Z","timestamp":1761464070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492220301021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1471492220301021"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2020.04.005","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}